T hrombosis is a dynamic process in which procoagulant activity, which promotes platelet activation and fibrin deposition, is balanced by physiologic anticoagulant and fibrinolytic activity. Historically, the treatment of thrombosis has been based on the use of agents that either inhibit procoagulant activity (i.e., anticoagulants) or induce fibrinolytic activity (i.e., plasminogen activators)....

ST-Segment Elevation Myocardial Infarction The Evolution from Fibrinolytic Therapy to a Fibrinolytic Strategy for Patients with Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2014 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation published online August 26, 2014; Circulation. http...

This study was performed to assess the effect of chlorpropamide therapy on the fibrinolytic activity of blood of maturity onset diabetics. Normal controls were also studied and the results compared with diabetics. Diabetics were found to have deficient fibrinolytic activity compared with non-diabetics but chlorpropamide did not appear significantly to affect this deficiency either in males or f...

STUDY OBJECTIVES To determine if intrapleural administration of methylprednisolone acetate (MA) after therapeutic thoracentesis for symptomatic malignant pleural effusion improved time to repeat thoracentesis for symptom control, quality of life (QOL), and dyspnea. DESIGN Double-blind, randomized, placebo-controlled trial. SETTING A tertiary care cancer treatment center in Edmonton, AB, Can...

The European Resuscitation Council Guidelines recommend the administration of fibrinolytic therapy when acute pulmonary embolism is a known or suspected cause cardiac arrest. However, contraindications that limit use fibrinolytics are sometimes challenged by clinicians, including head trauma in previous three weeks. We report on successful rescue patient with who had arrest emergency department...

Intrapleural fibrinolysins have been used to treat pleural loculations. However, the efficacy of clinically available agents has recently been questioned, providing a rationale for investigation of new interventions. Single-chain urokinase plasminogen activator resists inhibition by serpins, and repeated, daily intrapleural administration of this agent prevents intrapleural loculation more effe...